UBS Group’s DiaMedica Therapeutics DMAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $161K | Buy |
22,849
+14,188
| +164% | +$87.2K | ﹤0.01% | 6916 |
|
|
2026
Q1 | $58.6K | Buy |
8,661
+5,055
| +140% | +$40.1K | ﹤0.01% | 7274 |
|
|
2025
Q4 | $28.7K | Sell |
3,606
-9,734
| -73% | -$72.8K | ﹤0.01% | 7552 |
|
|
2025
Q3 | $91.6K | Buy |
13,340
+5,074
| +61% | +$27.5K | ﹤0.01% | 7181 |
|
|
2025
Q2 | $32.2K | Buy |
8,266
+3,884
| +89% | +$15.1K | ﹤0.01% | 8108 |
|
|
2025
Q1 | $16.6K | Buy |
4,382
+2,613
| +148% | +$14.9K | ﹤0.01% | 8349 |
|
|
2024
Q4 | $9.61K | Sell |
1,769
-10,970
| -86% | -$51.7K | ﹤0.01% | 8350 |
|
|
2024
Q3 | $53.4K | Buy |
+12,739
| New | +$47K | ﹤0.01% | 6777 |
|
|
2024
Q2 | – | Sell |
-1,926
| Closed | -$5.33K | – | 9628 |
|
|
2024
Q1 | $5.33K | Buy |
+1,926
| New | +$5.59K | ﹤0.01% | 7547 |
|
|
2023
Q4 | – | Sell |
-84
| Closed | -$217 | – | 9408 |
|
|
2023
Q3 | $217 | Buy |
+84
| New | +$270 | ﹤0.01% | 8685 |
|
|
2023
Q2 | – | Sell |
-2,038
| Closed | -$3.12K | – | 9048 |
|
|
2023
Q1 | $3.12K | Sell |
2,038
-1,719
| -46% | -$2.73K | ﹤0.01% | 8378 |
|
|
2022
Q4 | $5.94K | Sell |
3,757
-3,434
| -48% | -$4.63K | ﹤0.01% | 9106 |
|
|
2022
Q3 | $9K | Buy |
7,191
+4,161
| +137% | +$6.5K | ﹤0.01% | 8567 |
|
|
2022
Q2 | $6K | Buy |
3,030
+2,080
| +219% | +$4.85K | ﹤0.01% | 8663 |
|
|
2022
Q1 | $2K | Sell |
950
-3,668
| -79% | -$10.4K | ﹤0.01% | 9618 |
|
|
2021
Q4 | $17K | Buy |
+4,618
| New | +$18.1K | ﹤0.01% | 8054 |
|
|
2021
Q3 | – | Sell |
-20,715
| Closed | -$92K | – | 9634 |
|
|
2021
Q2 | $92K | Buy |
20,715
+19,665
| +1,873% | +$161K | ﹤0.01% | 5951 |
|
|
2021
Q1 | $10K | Buy |
1,050
+136
| +15% | +$1.27K | ﹤0.01% | 7917 |
|
|
2020
Q4 | $9K | Buy |
+914
| New | +$5K | ﹤0.01% | 7555 |
|
|
2020
Q3 | – | Sell |
-589
| Closed | -$4K | – | 8058 |
|
|
2020
Q2 | $4K | Sell |
589
-7,911
| -93% | -$35.3K | ﹤0.01% | 7442 |
|
|
2020
Q1 | $24K | Buy |
+8,500
| New | +$35.1K | ﹤0.01% | 6370 |
|
|
2019
Q4 | – | Sell |
-2,354
| Closed | -$5K | – | 8152 |
|
|
2019
Q3 | $5K | Buy |
2,354
+104
| +5% | +$336 | ﹤0.01% | 7463 |
|
|
2019
Q2 | $11K | Buy |
+2,250
| New | +$7.78K | ﹤0.01% | 7004 |
|
|
2019
Q1 | – | Sell |
-1,323
| Closed | -$4K | – | 7796 |
|
|
2018
Q4 | $4K | Buy |
+1,323
| New | +$4.16K | ﹤0.01% | 7622 |
|
Other funds holding DMAC
CLG
BL
UBS Group's DMAC Position: Q2 2026 in Review
UBS Group increased its DiaMedica Therapeutics (DMAC) stake by 164% in Q2 2026, buying an estimated $87.2K and bringing the position to 22,849 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #6916.
UBS Group first reported a position in DMAC in Q4 2018 and has held it in 24 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.
- UBS Group held 22,849 shares of DiaMedica Therapeutics worth $161K as of Q2 2026.
- UBS Group bought 14,188 DiaMedica Therapeutics shares in Q2 2026, an estimated $87.2K.
- DiaMedica Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6916 holding.
- UBS Group first reported a position in DiaMedica Therapeutics in Q4 2018 and has held it in 24 quarters since.
- 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.